The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
GHK-Cu shows potential as a regenerative agent in aesthetic medicine, but more rigorous clinical trials are needed to establish its efficacy and safety.
Where it sits
this study against the rest of the ghk-cu corpusSummary and findings
This systematic review evaluates the efficacy, safety, and regenerative mechanisms of GHK-Cu in aesthetic medicine. It included 20 studies, with 18 being preclinical and 2 randomized controlled trials (RCTs). The review found that GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls.
Abstract
The age-related decline in tissue regenerative capacity drives demand for interventions restoring physiological repair mechanisms. Glycyl-L-histidyl-L-lysine-copper (GHK-Cu) has demonstrated significant regenerative, anti-inflammatory, and antioxidant properties in preclinical models, prompting its increasing integration into aesthetic practice despite a paucity of standardized clinical guidelines. This systematic review evaluates the efficacy, safety, and regenerative mechanisms of GHK-Cu in aesthetic medicine to clarify its clinical utility and inform future research. A systematic search of PubMed, Embase, and Cochrane CENTRAL was conducted from database inception through March 2026, following PRISMA guidelines. Eligible studies included clinical and preclinical models investigating GHK-Cu as a standalone intervention for aesthetic applications. 20 studies (18 preclinical; 2 RCTs) were included. Preclinical data consistently demonstrated that GHK-Cu enhances extracellular matrix synthesis (type I collagen and glycosaminoglycans), modulates metalloproteinase activity, and promotes angiogenesis and cellular proliferation. It also exhibited significant anti-inflammatory effects by suppressing TGF-β and IL-6. Clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls. Additionally, advanced delivery systems, including microneedles and liposomes, markedly improved its transdermal bioavailability and efficacy. GHK-Cu demonstrates a reasonable biological basis for use as a regenerative agent in aesthetic medicine, supported by available preclinical data. Nevertheless, the findings reported across studies were constrained by methodological variability and a limited number of well-designed clinical trials. Future research incorporating larger, controlled trials with standardized formulations, dosing regimens, and delivery methods will be necessary to close the translational gap and inform the development of consistent therapeutic protocols in clinical practice.
Background
This paper addresses the age-related decline in tissue regenerative capacity and the demand for interventions that restore physiological repair mechanisms. GHK-Cu has shown significant regenerative, anti-inflammatory, and antioxidant properties in preclinical models. The study is important as it seeks to clarify the clinical utility of GHK-Cu in aesthetic medicine amidst a lack of standardized clinical guidelines.
Methods
A systematic search of PubMed, Embase, and Cochrane CENTRAL was conducted from database inception through March 2026, following PRISMA guidelines. Eligible studies included clinical and preclinical models investigating GHK-Cu as a standalone intervention for aesthetic applications. The review included 20 studies, with a focus on both efficacy and safety.
Results
Clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls. Preclinical data consistently demonstrated that GHK-Cu enhances extracellular matrix synthesis, modulates metalloproteinase activity, and promotes angiogenesis and cellular proliferation.
Interpretation
The findings suggest that GHK-Cu has a reasonable biological basis for use as a regenerative agent in aesthetic medicine, supported by available preclinical data. However, the effect size and clinical significance of the findings are not clearly defined, and the limitations of the study, including methodological variability and a small number of well-designed clinical trials, restrict the conclusions that can be drawn.
Key findings
- 20 studies included (18 preclinical; 2 RCTs).
- GHK-Cu significantly reduced wrinkle volume and depth compared with controls.
- Preclinical data showed GHK-Cu enhances extracellular matrix synthesis.
- GHK-Cu exhibited significant anti-inflammatory effects by suppressing TGF-β and IL-6.
- Advanced delivery systems improved transdermal bioavailability and efficacy.
Limitations
- 18 out of 20 studies were preclinical.
- Only 2 RCTs included.
- Methodological variability across studies.
- Limited number of well-designed clinical trials.
- Not enough data on standardized formulations and dosing regimens.